Roche expands in KRAS
GDC-7035 enters the clinic, as does another bispecific against PD-L1 and VEGF.
Gritstone has a mountain to climb with Granite
The group is persevering with Granite, but funds might be hard to come by.
Regor’s selective approach attracts Roche
For $850m up front Roche gets to challenge Pfizer.
ESMO 2024 – Bristol heads for phase 3 in small-cell
Backed by a slender survival signal the industry’s only anti-fucosyl-GM1 MAb is to go pivotal.
World Lung 2024 – Lilly eyes a first-line KRAS triplet
Data suggest a path forward for olomorasib plus Keytruda and chemo in PD-L1 low and negative patients.
